Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
3 evidence topics · 7 sources
Investigational dosage form: oral tablet
“The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses studied in phase 2 and phase 3 trials: 12.5 mg to 100 mg
“The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercial strengths and package sizes
No evidence found.